Company news

Zhejiang Jianfeng Group Co. Ltd. news in 2026

Zhejiang Jianfeng Group Co. Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing

November 5, 2026

(600668)"Zhejiang Jianfeng Group Co., Ltd."Report for Q3 2026

October 28, 2026

(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Key Operating Data for the First Three Quarters of 2026

October 28, 2026

(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading

October 16, 2026

(600668)"Zhejiang Jianfeng Group Co., Ltd."Announcement on Progress of Project Investment by a Controlled Subsidiary

October 11, 2026

Announcement on the Subsidiary's Receipt of the European CEP for Chemical API

September 24, 2026

Announcement on Progress in Providing Guarantee for Controlled Subsidiary

September 22, 2026

Announcement on the Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API

September 1, 2026

Announcement on Resolutions of the 18th Meeting of the 12th Board of Directors

August 30, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on the Proposed Winning Bid of Subsidiary in the National Centralized Drug Procurement

August 3, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Acquisition of Drug Registration Certificate by a Subsidiary

July 24, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

July 17, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Expected Loss in Semi-annual Performance for 2026

July 14, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Inclusion of the Subsidiary's Products in the "National Essential Medicines List (2026 Edition)"

July 10, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Implementation of Dividend Distribution for 2025

July 2, 2026

Zhe Jiang Jian Feng Group Co., Ltd.: Announcement on Subsidiary Obtaining the Approval Notice for Drug Supplementary Application

June 30, 2026

Announcement on Obtaining Drug Registration Certificate by Subsidiary

June 25, 2026

Announcement on Overdue Financial Assistance Provided by a Subsidiary

June 17, 2026

Announcement on Resignation of Directors

May 19, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 12, 2026

Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs

May 8, 2026

Report for Q1 2026

April 28, 2026

Announcement on Withdrawal of Drug Registration Application by the Subsidiary

April 24, 2026

Announcement on Implementation Result of Shares Repurchase and Share Changes

April 20, 2026

Notice on Convening the 2025 Annual General Meeting

April 13, 2026

Announcement on Progress in Repurchasing Shares through Call Auction

April 1, 2026

Announcement on Subsidiary Obtaining a Notice of Disapproval for the Drug Marketing Authorization Application

March 19, 2026

Earnings Preannouncement for 2025

January 27, 2026

Announcement on Withdrawal of Clinical Trail Application for Drug Registration by Subsidiary

January 15, 2026